⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
businesswire.com
AGEN
Agenus to Participate in Upcoming September Investor Conferences
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN
Form 8-K
sec.gov
AGEN
Form 8-K
sec.gov
AGEN
Cystic Fibrosis Screening: Laboratory Perspectives and Best Practices, Upcoming Webinar Hosted by Xtalks
prnewswire.com
AGEN
Form 8-K
sec.gov
AGEN
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
businesswire.com
AGEN
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
businesswire.com
AGEN
شركة Agenus تعلن عن نتائج بارزة لعلاج BOT+BAL تُظهر معدل بقاء إجمالي لمدة ثلاث سنوات بلغ 33% لدى مرضى سرطان القولون والمستقيم النقيلي من النوع MSS المقاوم للعلاج، ممن لا يعانون من نقائل كبدية نشطة، وذلك في مؤتمر ESMO GI 2026
businesswire.com
AGEN